19th November, 2018 -
Study published in Circulation Research
Patients with certain variants of the PATJ gene have less ability to recover after suffering a stroke. 7 out of every 10 patients who have this genetic variation are left with serious consequences three months after having a stroke, compared to less than half of sufferers who do not present this variation. These variants could indicate targets for future treatments that improve stroke prognosis, and enable personalised rehabilitation strategies. This has been revealed by the first multicentre study in this field, using data from more than 2,000 individuals and involving 12 centres around the world. The work was led by researchers from the Hospital del Mar Medical Research Institute as well as doctors from Hospital del Mar, with Genestroke Consortium groups and the collaboration of the International Stroke Genetics Consortium. The study was funded by La Marató de TV3.October 29th 2018 -
2 August 2018 -
Study published in Nature Communications
Researchers from the Hospital del Mar Medical Research Institute, with the support of IDIBELL and CIBERONC, have discovered that inhibiting the Jagged 1 protein prevents tumour growth in mice. This protein plays a key role in the development of the disease, because it activates the cell signal that allows cancer cells to grow and divide. The discovery leads the way to the development of a therapy for treating this type of pathology in humans, the second leading cause of cancer-related death in Western countries.July 12, 2018 -
March 19th -
21 december 2011 -
Personalized medicine against breast cancer
Triple-negative breast cancer (Estrogen Receptor-Negative, Progesterone Receptor-Negative, and HER-Negative) is a type of breast cancer with clinical characteristics and specific pathologies that represents a relevant clinic problem, as it affects around 20% of all women with breast cancer, and especially those who are young. On this basis, doctors from the Hospital del Mar and scientists from the IMIM (Institute of Medical Investigation of the Hospital del Mar) and the CRG (Center of Genomic Regulation) have now begun an ambitious project together with Roche Diagnostics to identify new therapeutic targets, as well as biomarkers that are predictive of the clinical evolution of this subtype of cancer.Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2024 Parc de Salut Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility